½ÃÀ庸°í¼­
»óǰÄÚµå
1638875

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2024-2032³â)

Bioprocess Validation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 135 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀåÀº 2023³â¿¡ 4¾ï 1,650¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2032³â±îÁö 10.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥À̼ÇÀº ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, °øÁ¤ÀÌ ÀϰüµÇ°Ô ³ôÀº ǰÁú°ú ¾ÈÀü Á¦Ç°À» Á¦°øÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¿øÀç·á »ç¿ëºÎÅÍ ÃÖÁ¾ Á¦Ç° »ý»ê¿¡ À̸£±â±îÁö ¸ðµç ´Ü°è°¡ ¾ö°ÝÇÑ ±ÔÁ¦ ¹× ǰÁú ¿ä±¸ »çÇ×À» ÃæÁ·ÇÏ´ÂÁö È®ÀÎÇϱâ À§ÇÑ Ã¼°èÀûÀÎ Å×½ºÆ® ¹× ºÐ¼®ÀÌ Æ÷ÇԵ˴ϴÙ.

½ÃÀåÀÇ È®´ë´Â ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, »ý¹° Á¦Á¦ ä¿ë Áõ°¡, °ËÁõ ±â¼úÀÇ Áøº¸°¡ ÁÖ¿ä ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ ºÎ¹®ÀÌ »ý»ê ´É·Â°ú ¾Æ¿ô¼Ò½Ì ¸ðµÎ¿¡¼­ ¼ºÀåÇÔ¿¡ µû¶ó ÄÄÇöóÀ̾𽺸¦ À¯ÁöÇϰí Á¦Ç° Ç¥ÁØÀ» À¯ÁöÇϱâ À§ÇÑ Á¾ÇÕÀûÀÎ °ËÁõ ÇÁ·ÎÅäÄÝÀÇ Çʿ伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. ´ÜÀÏŬ·Ð Ç×ü, ¹é½Å, À¯ÀüÀÚ Ä¡·á¿Í °°Àº »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõÀº ÀÌ·¯ÇÑ Ä¡·á°¡ ǰÁú, ¾ÈÀü¼º ¹× È¿´É¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±âÁØÀ» ÃæÁ·ÇØ¾ß Çϱ⠶§¹®¿¡ °ß°íÇÑ ¹ë¸®µ¥ÀÌ¼Ç ÇÁ·Î¼¼½ºÀÇ Çʿ伺À» ´õ¿í ³ô¿©ÁÖ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­´Â °Ë»ç À¯Çüº°·Î ºÐ·ùµÇ¸ç ÃßÃâ¹°¡¤¿ëÃâ¹° °Ë»ç, ¹Ì»ý¹°ÇÐÀû °Ë»ç, ¹«°á¼º °Ë»ç, ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º °Ë»ç µîÀÇ ºÐ¾ß°¡ Æ÷ÇԵ˴ϴÙ. 2023³â¿¡´Â ¹Ì»ý¹°ÇÐÀû °Ë»ç°¡ Áö¹èÀûÀÎ ºÎ¹®À¸·Î ºÎ»óÇÏ¿© 1¾ï 2,620¸¸ ´Þ·¯ÀÇ ¼öÀÍÀ» âÃâÇß½À´Ï´Ù. ±ÔÁ¦±â°üÀº Á¦Á¶ °øÁ¤ Àü¹Ý¿¡ °ÉÃÄ ¹«±Õ¼º°ú ǰÁúÀ» º¸ÀåÇÏ´Â ¹Ì»ý¹°ÇÐÀû ½ÃÇèÀÇ Á߿伺À» °­Á¶ÇÕ´Ï´Ù. ÀûÀýÇÑ Á¦Á¶ ±Ô¹ü(GMP) Áؼö ¹× ÀÏ»óÀûÀΠȯ°æ ¸ð´ÏÅ͸µÀº ¹ÙÀÌ¿À ÀǾàǰÀÇ ¹«°á¼ºÀ» º¸È£ÇÏ´Â µ¥ ÇʼöÀûÀ̸ç ÀÌ °Ë»ç ¹üÁÖÀÇ Á߿伺À» °­Á¶ÇÕ´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2023³â
¿¹Ãø ¿¬µµ 2024-2032³â
½ÃÀÛ ±Ý¾× 4¾ï 1,650¸¸ ´Þ·¯
¿¹Ãø ±Ý¾× 10¾ï 3,000¸¸ ´Þ·¯
CAGR 10.7%

¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀåÀº ½ºÅ×ÀÌÁöº°·Î °øÁ¤ ¼³°è, °øÁ¤ Àû°Ý¼º È®ÀÎ, Áö¼ÓÀûÀÎ °øÁ¤ °ËÁõÀ¸·Î ºÐ·ùµË´Ï´Ù. 2023³â¿¡´Â °øÁ¤ ÀÚ°Ý È®ÀÎÀÌ ½ÃÀåÀÇ 46.8%¸¦ Â÷ÁöÇϸç ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ´Ü°è´Â Á¦Á¶ °øÁ¤ÀÌ È®¸³µÈ ¸Å°³º¯¼ö ³»¿¡¼­ ÀϰüµÇ°Ô Á¦Ç°À» »ý»êÇÏ´ÂÁö È®ÀÎÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ½ÇÁ¦ ÀÛµ¿ Á¶°ÇÀ» ½Ã¹Ä·¹ÀÌÆ®ÇÔÀ¸·Î½á °øÁ¤ ÀÚ°Ý È®ÀÎÀº ¹ÙÀÌ¿À Á¦Á¶ ÇÁ·ÎÅäÄÝÀÇ ½Å·Ú¼º°ú ÀçÇö¼ºÀ» º¸ÀåÇÏ°í °øÁ¤ ¼³°è¿Í Áö¼ÓÀûÀÎ °ËÁõ ´Ü°è¸¦ ±³Â÷ÇÕ´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2023³â¿¡ 1¾ï 7,450¸¸ ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£ µ¿¾È CAGR 10.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹Ì±¹ÀÇ ±ÔÁ¦ »óȲ¿¡¼­´Â FDA¿Í °°Àº ±â°üÀÌ ¾ö°ÝÇÑ À¯È¿¼º °Ë»ç¸¦ Àǹ«È­Çϰí ÀÖ½À´Ï´Ù. GMP ±âÁØÀ» ÁؼöÇÏ·Á¸é ¸ðµç Á¦Á¶ ´Ü°è¿¡¼­ öÀúÇÑ °ËÁõÀÌ ÇÊ¿äÇϸç Çõ½ÅÀûÀÎ °ËÁõ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼ºÀåÇÏ´Â ¹ÙÀÌ¿À ÀǾàǰ »ê¾÷Àº ±ÔÁ¦ ¾Ð·Â°ú »ý¹° Á¦Á¦ÀÇ º¸±Þ·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥À̼ÇÀ» Çö´ë °Ç°­ °ü¸® Á¦Á¶ÀÇ ÇÙ½ÉÀ¸·Î ÀÚ¸® ¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¾ÈÀü¼º°ú ǰÁú¿¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
      • ¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • »ý¸í°úÇÐ ºÐ¾ßÀÇ ¿¬±¸°³¹ßºñ Áõ°¡
      • ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥À̼ÇÀÇ ¾Æ¿ô¼Ò½Ì ¼ö¿ä Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
      • °ËÁõÀÇ º¹À⼺°ú ½Ã°£ Áý¾àÀû Ư¼º
      • ¹ë¸®µ¥ÀÌ¼Ç ÇÁ·Î¼¼½º¿¡ µû¸¥ ³ôÀº ºñ¿ë
  • ¼ºÀå °¡´É¼ºÀÇ ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • Àå·¡ ½ÃÀå µ¿Çâ
  • °¸ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߰衤¿¹Ãø : °Ë»ç À¯Çüº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ÃßÃâ¹°/ħÃâ¹° °Ë»ç
  • ¹Ì»ý¹° °Ë»ç
  • ¹«°á¼º ½ÃÇè
  • ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º °Ë»ç
  • ºÒ¼ø¹° °Ë»ç
  • ¸¶ÀÌÄÚÇö󽺸¶ °Ë»ç
  • ¹°¸®È­ÇÐÀû ½ÃÇè
  • ÀûÇÕ¼º ½ÃÇè
  • ±âŸ °Ë»ç À¯Çü

Á¦6Àå ½ÃÀå Ã߰衤¿¹Ãø : ½ºÅ×ÀÌÁöº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ÇÁ·Î¼¼½º ¼³°è
  • ÇÁ·Î¼¼½º °ËÁõ
  • Áö¼ÓÀûÀÎ ÇÁ·Î¼¼½º °ËÁõ

Á¦7Àå ½ÃÀå Ã߰衤¿¹Ãø : ¸ðµåº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ÀÎÇϿ콺
  • ¾Æ¿ô¼Ò½Ì

Á¦8Àå ½ÃÀå Ã߰衤¿¹Ãø : ¿ëµµº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ¹ÙÀÌ¿ÀÀǾàǰ
  • À¯ÀüÀÚ¡¤¼¼Æ÷ Ä¡·á
  • ¹é½Å
  • ±âŸ ¿ëµµ

Á¦9Àå ½ÃÀå Ã߰衤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • Á¦¾à±â¾÷
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • CRO ¹× CDMO
  • Çмú±â°ü ¹× ¿¬±¸±â°ü

Á¦10Àå ½ÃÀå Ã߰衤¿¹Ãø : Áö¿ªº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Asahi Kasei Corporation
  • Bio-Rad Laboratories
  • Charles River Laboratories
  • Danaher Corporation
  • Eurofins Scientific
  • Lonza Group
  • Meissner Filtration Products
  • Merck KGaA
  • Pace Analytical Services
  • Repligen Corporation
  • Sartorius AG
  • SGS SA
  • Thermo Fisher Scientific
  • Tosoh Corporation
  • WuXi AppTec
KTH 25.03.04

The Global Bioprocess Validation Market reached USD 416.5 million in 2023 and is anticipated to grow at 10.7% CAGR from 2024 to 2032. Bioprocess validation plays a critical role in biopharmaceutical manufacturing, ensuring that processes consistently deliver products of high quality and safety. It involves systematic tests and analyses to verify that every stage, from raw material usage to final product output, meets strict regulatory and quality requirements.

The market expansion is largely driven by stringent regulatory demands, rising adoption of biologics, and advancements in validation technologies. As the biopharmaceutical sector grows, both in production capacity and outsourcing, there is an increasing need for comprehensive validation protocols to maintain compliance and uphold product standards. The surging demand for biologics, including monoclonal antibodies, vaccines, and gene therapies, further amplifies the necessity for robust validation processes, as these therapies must meet exacting standards for quality, safety, and efficacy.

Segmented by testing types, the market encompasses areas such as extractables and leachables testing, microbiological testing, integrity testing, and viral clearance testing, among others. In 2023, microbiological testing emerged as a dominant segment, generating USD 126.2 million in revenue. Regulatory bodies emphasize the importance of microbiological testing in ensuring sterility and quality throughout the manufacturing process. Adherence to Good Manufacturing Practices (GMP) and routine environmental monitoring are critical to safeguarding the integrity of biopharmaceutical products, underscoring the significance of this testing category.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$416.5 Million
Forecast Value$1.03 Billion
CAGR10.7%

By stage, the bioprocess validation market is categorized into process design, process qualification, and continued process verification. Process qualification accounted for the largest share in 2023, representing 46.8% of the market. This stage is essential in confirming that manufacturing processes consistently produce products within established parameters. By simulating real operating conditions, process qualification ensures the reliability and reproducibility of biomanufacturing protocols, bridging process design, and ongoing verification phases.

U.S. market reached USD 174.5 million in 2023 and is projected to grow at a CAGR of 10.8% during the forecast period. The regulatory landscape in the U.S. mandates rigorous validation practices driven by agencies such as the FDA. Compliance with GMP standards necessitates thorough validation of all manufacturing stages, prompting increased investments in innovative validation techniques.

The growing biopharmaceutical industry, coupled with regulatory pressures and the rising prevalence of biologics, positions bioprocess validation as a cornerstone of modern healthcare manufacturing.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Stringent regulations regarding safety and quality
      • 3.2.1.2 Increasing demand for biopharmaceuticals
      • 3.2.1.3 Rising R&D expenditure in life sciences sector
      • 3.2.1.4 Increasing demand for bioprocess validation outsourcing
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Complexity and time-intensive nature of validation
      • 3.2.2.2 High costs associated with validation processes
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Testing Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Extractables/leachables testing
  • 5.3 Microbiological testing
  • 5.4 Integrity testing
  • 5.5 Viral clearance testing
  • 5.6 Adventitious agent testing
  • 5.7 Mycoplasma testing
  • 5.8 Physicochemical testing
  • 5.9 Compatibility testing
  • 5.10 Other testing types

Chapter 6 Market Estimates and Forecast, By Stage, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Process design
  • 6.3 Process qualification
  • 6.4 Continued process verification

Chapter 7 Market Estimates and Forecast, By Mode, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 In-house
  • 7.3 Outsourced

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Biopharmaceuticals
  • 8.3 Gene and cell therapy
  • 8.4 Vaccines
  • 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Pharmaceutical companies
  • 9.3 Biotechnology companies
  • 9.4 CROs and CDMOs
  • 9.5 Academic and research institutes

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Asahi Kasei Corporation
  • 11.2 Bio-Rad Laboratories
  • 11.3 Charles River Laboratories
  • 11.4 Danaher Corporation
  • 11.5 Eurofins Scientific
  • 11.6 Lonza Group
  • 11.7 Meissner Filtration Products
  • 11.8 Merck KGaA
  • 11.9 Pace Analytical Services
  • 11.10 Repligen Corporation
  • 11.11 Sartorius AG
  • 11.12 SGS S.A.
  • 11.13 Thermo Fisher Scientific
  • 11.14 Tosoh Corporation
  • 11.15 WuXi AppTec
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦